Back to articles

KRAS gene mutation testing strongly recommended by ASCO


The American Society of Clinical Oncology (ASCO) now recommends that all patients with metastatic colorectal cancer who are candidates for anti–epidermal growth factor receptor monoclonal antibody (anti-EGFR) therapy such as cetuximab (Erbitux—Bristol-Myers Squibb, ImClone) or panitumumab (Vectibix—Amgen) have tumor cells tested for KRAS mutations, as data show that patients with KRAS mutations do not benefit from these therapies.